Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study

By sjmartinez • February 4, 2025

Thyssen JP, Rosmarin D, Costanzo A, Warren R, Chu CY, Chovatiya R, Ladizinski B, Hu X, Liu Y, Calimlim B, Nduaka C, Vigna N, Armstrong A. Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study. Dermatology. 2025;241(1):10-18. doi: 10.1159/000542275. Epub 2024 Oct 30. PMID: 39476813.

Tags: atopic dermatitis, Body region, Dermatology, Dupilumab, EASI, eczema, Publications, Upadacitinib

Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials

Armstrong AW, Lebwohl M, Warren RB, Sofen H, Morita A, Paul C, Papp KA, Colombo MJ, Scotto J, Vaile J, Zhuo J, Vritzali E, Berger[...]

Ethical Considerations in Recommending Patients Avoid Cosmetic Treatments Performed by Non-Physician Providers

Hill RC, Grant-Kels JM, Farshchian M. Ethical Considerations in Recommending Patients Avoid Cosmetic Treatments Performed by Non-Physician Providers. J Am Acad Dermatol. 2025 Feb 24:S0190-9622(25)00356-1.[...]

Validation of DermSat-7 for Assessing Treatment Satisfaction in Patients With Psoriasis

Armstrong AW, Lee K, Yee D, Woodbury M, Zundell M, Zagona-Prizio C, Yousif J, Grant C, Shields A, Chou P, Callis Duffin K, Gottlieb AB,[...]